News & Events

Published On: 12/15/2021

Target RWE Dermatology Study Data Shared at 3rd Annual RAD Conference

Latest real-world TARGET-DERM AD abstract posters accepted to virtual event

In December 2021, Target RWE participated in the annual Revolutionizing Atopic Dermatitis (RAD) conference and presented two posters from the company’s active longitudinal real-world study, TARGET-DERM AD.

The first poster (#632) entitled, Epidemiology and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM-AD cohort, was selected for oral presentation. It was presented by Lawrence Eichenfield, MD, Professor of Dermatology and Pediatrics at Rady Children’s Hospital in San Diego, CA. This real-world analysis of patients with AD found that difficult to treat areas were associated with significantly higher impact on health-related quality of life (HRQoL). In addition, patients with affected head, face, neck, or hands were more likely than those without to have severe disease than those who did not (28.5% vs. 16.3%, p=0.02). These TARGET-DERM AD results highlight the importance of detailed assessment of specific areas affected by AD for more personalized approaches to best address the needs of patients.

The second TARGET-DERM AD abstract poster (#644) was titled Disease burden in atopic dermatitis is associated with higher symptom severity and lower quality of life: TARGET-DERM AD real world study. This analysis aimed to highlight associations between clinician-reported validated Investigator Global Assessment for AD (vIGA-AD) and patient-reported burden of disease. The study found that greater disease severity is significantly associated with higher symptom severity and lower quality of life.

“The real-world data findings presented at this year’s RAD conference underline the importance of detailed documentation and generation of research in the field of atopic dermatitis,” said Target RWE Vice President of RWE and Strategic Partnerships, Julie Crawford, MD.

TARGET-DERM is a global observational study following adult and pediatric patients with immune-mediated inflammatory skin conditions from the U.S., Canada, and Europe. Learn more about Target RWE’s publications here.

About Target RWE

As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.

Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model.


Kayla Slake
Marketing Manager

984.234.0268 ext 205